ATE275200T1 - Genabgabe-vehikel die das apoptosis vp2 inducierendes protein, und/oder apoptin exprimiert - Google Patents

Genabgabe-vehikel die das apoptosis vp2 inducierendes protein, und/oder apoptin exprimiert

Info

Publication number: ATE275200T1
Authority: AT; Austria
Prior art keywords: apoptosis; gene delivery; delivery vehicles; apoptin; relates
Prior art date: 1997-04-15

Application number

AT98914146T

Other languages

English (en)

Inventor

Matheus Hubertus Mari Noteborn

Alexandra Maria Pietersen

Original Assignee

Leadd Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-15

Filing date

1998-04-15

Publication date

2004-09-15

1997-04-15 Priority claimed from EP97201121A external-priority patent/EP0872552A1/de

1998-04-15 Application filed by Leadd Bv filed Critical Leadd Bv

2004-09-15 Application granted granted Critical

2004-09-15 Publication of ATE275200T1 publication Critical patent/ATE275200T1/de

Links

238000001476 gene delivery Methods 0.000 title abstract 3
101710094856 Apoptin Proteins 0.000 title abstract 2
230000006907 apoptotic process Effects 0.000 title abstract 2
108090000623 proteins and genes Proteins 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
210000004881 tumor cell Anatomy 0.000 abstract 2
102000010565 Apoptosis Regulatory Proteins Human genes 0.000 abstract 1
108010063104 Apoptosis Regulatory Proteins Proteins 0.000 abstract 1
241000725585 Chicken anemia virus Species 0.000 abstract 1
206010058314 Dysplasia Diseases 0.000 abstract 1
206010054949 Metaplasia Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108010067390 Viral Proteins Proteins 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
206010020718 hyperplasia Diseases 0.000 abstract 1
230000006882 induction of apoptosis Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000003211 malignant effect Effects 0.000 abstract 1
230000015689 metaplastic ossification Effects 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Zoology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Plant Pathology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT98914146T 1997-04-15 1998-04-15 Genabgabe-vehikel die das apoptosis vp2 inducierendes protein, und/oder apoptin exprimiert ATE275200T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP97201121A EP0872552A1 (de)	1997-04-15	1997-04-15	Genabgabe-Vehikel die das Apoptosis VP2 induzierendes Protein und/oder Apoptin exprimiert
EP97203595A EP0878546A1 (de)	1997-04-15	1997-11-18	Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
PCT/NL1998/000213 WO1998046760A1 (en)	1997-04-15	1998-04-15	A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin

Publications (1)

Publication Number	Publication Date
ATE275200T1 true ATE275200T1 (de)	2004-09-15

Family

ID=26146368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98914146T ATE275200T1 (de)	1997-04-15	1998-04-15	Genabgabe-vehikel die das apoptosis vp2 inducierendes protein, und/oder apoptin exprimiert

Country Status (17)

Country	Link
EP (2)	EP0878546A1 (de)
JP (1)	JP2001521387A (de)
KR (1)	KR100528755B1 (de)
AT (1)	ATE275200T1 (de)
AU (1)	AU750162B2 (de)
BR (1)	BR9808542A (de)
CA (1)	CA2286165C (de)
CZ (1)	CZ299963B6 (de)
DE (1)	DE69825978T2 (de)
DK (1)	DK0975764T3 (de)
ES (1)	ES2227822T3 (de)
NO (1)	NO994967L (de)
NZ (1)	NZ500012A (de)
PL (1)	PL196607B1 (de)
PT (1)	PT975764E (de)
SK (1)	SK285724B6 (de)
WO (1)	WO1998046760A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2301401C (en)	1997-08-12	2008-10-21	Leadd B.V.	Determining the transforming capability of agents
AU2004233486B2 (en) *	1999-01-11	2007-09-13	Leadd B.V.	Use of apoptosis inducing agents in the treatment of (auto)immune diseases
EA200100770A1 (ru) *	1999-01-11	2002-02-28	Леадд Б.В.	Применение агентов, индуцирующих апоптоз, в лечении (ауто)имунных заболеваний
PT1083224E (pt) *	1999-09-02	2007-03-30	Leadd Bv	Proteína associada a apoptina
EP1081226A1 (de) *	1999-09-02	2001-03-07	Leadd B.V.	Apoptin-bindendes Protein
JP2003516152A (ja) *	1999-12-10	2003-05-13	レアトベー．フェー．	アポプチン会合タンパク質
DE60229924D1 (de) *	2001-03-30	2009-01-02	Leadd Bv	Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
KR100561985B1 (ko)	2004-07-03	2006-03-22	고려대학교 산학협력단	종양 특이적 아폽틴 발현 카세트 및 이를 포함하는아데노바이러스 발현 벡터
KR100877824B1 (ko)	2005-11-11	2009-01-12	한국생명공학연구원	Ｅ2ｅｐｆｕｃｐ-ｖｈｌ 상호작용 및 그 용도
CN109111527B (zh) *	2018-08-03	2022-03-15	沈阳金石生物制药有限公司	靶向特异性诱导肿瘤细胞凋亡的gip34-vp3融合蛋白及其制备方法和应用
CN109266714A (zh) *	2018-10-12	2019-01-25	广州医科大学	一种循环肿瘤细胞的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL9301272A (nl) *	1993-07-20	1995-02-16	Aesculaap Bv	Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus.
NL9002008A (nl) *	1990-09-12	1992-04-01	Stichting Centr Diergeneeskund	Recombinant dna en rna en daarvan afgeleide produkten.
FR2732348B1 (fr) *	1995-03-31	1997-04-30	Rhone Poulenc Rorer Sa	Systeme d'expression conditionnel

1997
- 1997-11-18 EP EP97203595A patent/EP0878546A1/de not_active Withdrawn
1998
- 1998-04-15 DK DK98914146T patent/DK0975764T3/da active
- 1998-04-15 CZ CZ0349399A patent/CZ299963B6/cs not_active IP Right Cessation
- 1998-04-15 CA CA002286165A patent/CA2286165C/en not_active Expired - Fee Related
- 1998-04-15 SK SK1428-99A patent/SK285724B6/sk not_active IP Right Cessation
- 1998-04-15 ES ES98914146T patent/ES2227822T3/es not_active Expired - Lifetime
- 1998-04-15 PL PL336312A patent/PL196607B1/pl unknown
- 1998-04-15 JP JP54377198A patent/JP2001521387A/ja active Pending
- 1998-04-15 AT AT98914146T patent/ATE275200T1/de not_active IP Right Cessation
- 1998-04-15 BR BR9808542-5A patent/BR9808542A/pt not_active Application Discontinuation
- 1998-04-15 AU AU68563/98A patent/AU750162B2/en not_active Ceased
- 1998-04-15 NZ NZ500012A patent/NZ500012A/en unknown
- 1998-04-15 PT PT98914146T patent/PT975764E/pt unknown
- 1998-04-15 DE DE69825978T patent/DE69825978T2/de not_active Expired - Fee Related
- 1998-04-15 EP EP98914146A patent/EP0975764B1/de not_active Expired - Lifetime
- 1998-04-15 KR KR10-1999-7009550A patent/KR100528755B1/ko not_active Expired - Fee Related
- 1998-04-15 WO PCT/NL1998/000213 patent/WO1998046760A1/en not_active Ceased
1999
- 1999-10-12 NO NO994967A patent/NO994967L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO994967L (no)	1999-12-15
NZ500012A (en)	2001-04-27
EP0975764A1 (de)	2000-02-02
CA2286165A1 (en)	1998-10-22
DK0975764T3 (da)	2005-01-03
SK142899A3 (en)	2000-06-12
EP0975764B1 (de)	2004-09-01
DE69825978D1 (de)	2004-10-07
AU6856398A (en)	1998-11-11
SK285724B6 (sk)	2007-07-06
EP0878546A1 (de)	1998-11-18
KR20010006460A (ko)	2001-01-26
DE69825978T2 (de)	2005-09-15
CZ349399A3 (cs)	2000-02-16
WO1998046760A1 (en)	1998-10-22
AU750162B2 (en)	2002-07-11
PL196607B1 (pl)	2008-01-31
JP2001521387A (ja)	2001-11-06
NO994967D0 (no)	1999-10-12
BR9808542A (pt)	2000-05-23
CZ299963B6 (cs)	2009-01-07
KR100528755B1 (ko)	2005-11-15
CA2286165C (en)	2009-02-03
PT975764E (pt)	2004-11-30
PL336312A1 (en)	2000-06-19
ES2227822T3 (es)	2005-04-01

Legal Events

Date

Code

Title

Description

2005-07-15

UEP

Publication of translation of european patent specification

Ref document number: 0975764

Country of ref document: EP

2010-01-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
FI95472B (fi)	1995-10-31	Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
DE69825978D1 (de)	2004-10-07	Genabgabe-vehikel die das apoptosis vp2 inducierendes protein, und/oder apoptin exprimiert
PT797676E (pt)	2006-05-31	Vector adenoviral recombinante e metodos de utilizacao
NO20004631D0 (no)	2000-09-15	Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
BR0009505A (pt)	2002-06-11	Compostos e processos para terapia e diagnóstico de câncer de pulmão
HUP0002095A2 (hu)	2000-10-28	Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
ES2061708T3 (es)	1994-12-16	Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus.
ATE229977T1 (de)	2003-01-15	Peptide mit antiproliferativen eigenschaften
ATE363489T1 (de)	2007-06-15	In tumoren vervielfältigte gensequenzen und deren diagnostische verwendungen
DE3683482D1 (de)	1992-02-27	Cdns und gen fuer menschliches angiogenin (angiogenesis-faktor) und expression.
HUP9903921A2 (hu)	2000-03-28	Tumor nekrózis faktorral rokon ligandum
CA2167578A1 (en)	1995-02-02	Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor
EP1536006A4 (de)	2006-07-19	Krebsantigene und deren nutzung
Wu et al.	1994	DNA alterations in cells from hereditary non-polyposis colorectal cancer patients
ATE152629T1 (de)	1997-05-15	Diagnose von krebs-metastasen durch das mts-1 gen
DK498387D0 (da)	1987-09-22	Virus-dna-sekvens
ATE501255T1 (de)	2011-03-15	84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt
DK0817859T3 (da)	2002-04-29	Rekombinante DNA vektorer til Genterapi
Franzen	1997	A two-dimensional gel electrophoretic study of proteins in tumours of the lung and breast.
ATE210990T1 (de)	2002-01-15	Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
WO2000071564A3 (en)	2003-05-01	Isolated nucleic acids of the p-hyde family, p-hyde proteins, and methods of inducing susceptibility to induction of cell death in cancer
WO2002004596A3 (en)	2002-04-18	Diagnosing and treating cancer cells using mutant viruses
CO5050254A1 (es)	2001-06-27	Compuestos para el tratamiento y diagnostico del cancer de pulmon